Fri 3/22/2019 04:35 ET
S&P 5002854.8831.121.09%BANKS427.326.321.48%OIL59.780.200.33%BITCOIN3998.782.000.05%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Stocks For A Different Jungle (Aratana Therapeutics, Inc - PETX)    If it belongs at the Pit it doesn't belong here.

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add PETX
From: singhtelecom (Rep: 959)Date: 05/06/2018 05:22
Forum: Stocks For A Different Jungle - Msg #19147 - List PETX msgs Thread #674007452 (Rec: 0)
The Activist Spotlight
Aratana Therapeutics (PETX)
Business: develops and commercializes biopharmaceuticals for pets
Stock Market Value: $232 million ($5.07/share)
Investor’s Avg Cost: $5.00/share
What’s Happening:Engaged Capital has nominated three candidates for the board at the 2018 annual meeting.

Key Numbers:
$12 million: money raised by PETX last quarter by selling small lots of shares through brokers
$10 million:the amount of the $12 million raised by PETX that likely came from Engaged
5.2%: PETX common shares owned by Engaged

Behind the Scenes: Aratana is one of the few businesses in the pet-care industry that, as an independent entity, is successfully commercializing drugs. It has three early-stage drugs currently being marketed, with several more in the pipeline. While there is a lot of potential here, Aratana is not yet cash-flow positive, and only has about 12 months of cash left. That’s created a lot of concern among the shareholders.

Engaged has nominated one director with bankruptcy experience, one with industry experience, and one with operating experience. The directors will have two objectives: first, streamlining operations and holding management accountable to stretch the remaining cash as long as possible; and second, instilling a sense of urgency in management about exploring a sale of the company so they do not end up in a fire sale, running out of cash.

Aratana could be an attractive acquisition for a larger pharmaceutical company such as Eli Lilly, Zoetis, Bayer, Merck, or Sanofi, who can eliminate corporate overhead, easily absorb other expenses, and leverage its infrastructure to market the acquired drugs.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser singhtelecom: Reward | Watch | IgnorePETX: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add PETX | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.